Male infertility due to sulphasalazine

R. TOBIAS*  
M.B., Ch.B., M.R.C.P.  

T. COETZEE†  

K. E. SAPIRE†  
M.B., Ch.B.  

I. N. MARKS*‡  
B.Sc., M.B., Ch.B., F.R.C.P.(Ed.) F.A.C.G.  

*Gastrointestinal Clinic, Groote Schuur Hospital, Cape Town; †Department of Obstetrics and Gynaecology, and ‡Department of Medicine, Cape Town Medical School, Cape Town, South Africa

Summary
A male patient presented with infertility and was found to have severe oligospermia and a low serum testosterone. Three months after stopping sulphasalazine, both abnormalities returned to normal and his wife subsequently became pregnant.

Introduction
Sulphasalazine-induced oligospermia has recently been recognized (Toth, 1979; Levi et al., 1979; Grieve, 1979), but concomitant low serum testosterone concentration has not been documented. A case of reversible oligospermia and low serum testosterone due to sulphasalazine is reported.

Case report
A 39-year-old white male with a 15-year history of ulcerative colitis involving the left colon was admitted to hospital on 2 July 1980 with acute symptoms. He had been on sulphasalazine 1 g twice/day for at least one year before admission. His past history included hepatitis, malaria and non-specific urethritis. The latter resulted in an urethral stricture, requiring intermittent dilatations, the last of which had been performed 5 years previously. Physical examination was unremarkable apart from the sigmoidoscopic findings of grade 3–4 colitis. His symptoms remitted on prednisone 60 mg daily, prednisolone enemas twice/day and increasing the sulphasalazine to 1 g thrice/day. He was discharged on the 11 July on that dose of sulphasalazine and prednisone 45 mg daily, reducing to 30 mg over the next month.

On 15 August a semen analysis was performed because of his wife’s infertility after 18 months of marriage. This showed the presence of ‘occasional dead sperms’ only. Serum hormone levels were (normal ranges in brackets): luteinizing hormone (LH)—8·2 mi.u./ml (5–15 mi.u./ml); follicle stimulating hormone (FSH)—16·7 mi.u./ml (5–15 mi.u./ml) and testosterone—5·4 nmol/l (10–55 nmol/l). The sulphasalazine was immediately stopped and the prednisone reduced to 15 mg daily over the following month.

On 19 September the hormone levels were: LH—4·7 mi.u./ml; FSH—11·3 mi.u./ml and testosterone—7·9 nmol/l. He was on 15 mg of prednisone daily. During the following month he had an exacerbation of symptoms and the dose of prednisone was increased to 80 mg daily, but sulphasalazine was withheld.

On 28 November he was symptom-free and taking prednisone 10 mg daily. Serum testosterone was normal—12·4 nmol/l and the semen analysis was compatible with fertility at 138·5 × 10⁶/ml. On the 21 February 1981 his wife’s pregnancy was confirmed.

Discussion
Sulphasalazine was first used in clinical practice in 1942 (Svartz, 1942). It is composed of sulphapyridine and 5-aminosalicylate (5-ASA) linked through an azo bond (salicylosulphapyridine). About 15% is absorbed as the parent drug and the rest splits into its component agents. It is used for maintenance therapy in inflammatory bowel disease and the therapeutic effect is exerted through the 5-ASA of which 80% is excreted through the bowel. The association with infertility was recognized in 1975 (Grieve, 1979) but the first reports of reversible oligospermia with resultant pregnancy were only published in 1979 (Toth, 1979; Levi et al., 1979).

The cause of oligospermia due to sulphasalazine therapy is not known, but several theories are postulated. Sulphasalazine is a competitive inhibitor of the enzyme system for folic acid transport across the bowel wall (Selhub, Jeelani Dhar and Rosenberg, 1978) and may suppress the rapid turnover of cells
which occur in spermatogenesis. Prostaglandin concentrations (PgE₂) are lower in seminal fluid of subfertile men and raised concentrations can increase sperm motility in vitro (Bygdeman, 1969). Seventy-seven per cent. to 98% inhibition of prostaglandin turnover occurs in men on therapeutic doses of salicylates and larger doses of aspirin reduce seminal prostaglandin concentration by 50% after 2–6 days. Two to 3 g of sulphasalazine would yield only one-third of the therapeutic dose of aspirin, but this may cause partial suppression of prostaglandin synthesis (Toth, 1979).

In view of this patient’s reversible low serum testosterone, a third possible mechanism is suggested. This hormone is secreted from the Leydig cells and is essential for the development of male accessory sex organs, prostate, seminal vesicles and semen production. It acts directly on the seminiferous tubules and the amount of testosterone ‘bathing’ the tubules is important for spermatogenesis (Pepperell, Hudson and Wood, 1980). Testosterone synthesis and spermatogenesis are controlled by the hypothalamic pituitary axis. LH acts on Leydig cells to induce testosterone synthesis and FSH initiates spermatogenesis. In this patient, both FSH and LH levels were normal and the sulphasalazine appears to have had a direct suppressive effect on the Leydig cells. Several drugs can block one or more enzymes necessary for the synthesis of testosterone from cholesterol, resulting in impaired spermatogenesis (Amelar, Dubin and Walsh, 1977). Although a testicular biopsy was not performed in the present patient, this may be the mechanism by which the sulphasalazine acted, rather than by structural damage to the cells. The rapid reversibility tends to support this theory.

Apart from a reduced count, the spermatozoa of men on sulphasalazine have shown reduced motility and morphological abnormalities of the head, midpiece and tail segments. A characteristic ‘megalo’-cell type has been reported in 3–8% of spermatozoa, but this may only represent an increased osmotic fragility of the head (Toth, 1979). Toovey, Levi and Hendry (1980) reported on the semen analysis of 18 patients with inflammatory bowel disease who were on long-term sulphasalazine therapy. Eight had complained of infertility. Of the specimens examined, sperm density was below normal in 15 out of 17; motility was reduced in all 18 patients and morphology was abnormal in 10 out of 16. There were no significant differences in these 3 parameters whether patients complained of infertility or not. Thus, sulphasalazine appears to have a significant effect on spermatogenesis and fertility, but this does not become apparent unless the patient complains. The changes are usually reversible within 3 months of stopping the drug and conception usually follows.

Prednisolone has been shown to inhibit spermatogenesis if administered at a dosage of 30 mg daily for at least one month, but these changes may not revert to normal even at 6 months (Mancini et al., 1966). In view of the present patient’s relatively rapid recovery and the fact that he was on prednisone 80 mg daily within one month before his second semen analysis, it seems unlikely that this drug played a part in his oligospermia. Levi et al. (1979) described a patient whose oligospermia returned to normal despite his remaining on 25 mg prednisone and prednisolone enemas daily.

The use of sulphasalazine as a male contraceptive has been considered. Whatever its mode of action, it does not appear to cause serious damage as it is readily reversible. However, other side effects of the parent molecule preclude its use and research is being aimed at isolating the active principle without the hazards of the sulphur moiety (Levi, Toovey and Hudson, 1981). When prescribing this drug to young male patients, doctors should be alert to the possibility of iatrogenic infertility.

Acknowledgments
We thank Dr H. R. Sanders, Principal Medical Superintendent at Groote Schuur Hospital for permission to publish, and Mrs M. Bloch for typing the manuscript.

References
Male infertility due to sulphasalazine

R. Tobias, T. Coetzee, K. E. Sapire and I. N. Marks

Postgrad Med J 1982 58: 102-103
doi: 10.1136/pgmj.58.676.102

Updated information and services can be found at:
http://pmj.bmj.com/content/58/676/102

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/